Pneumococcal Disease News and Research

RSS
Pneumococcal disease describes a group of illnesses caused by the bacterium Streptococcus pneumoniae, also known as pneumococcus. This bacterial pathogen, which affects both children and adults, is a major cause of death and illness worldwide. In fact, according to the World Health Organization (WHO), pneumococcal disease is the number one vaccine-preventable cause of death in children younger than 5 years of age worldwide.
Study finds feasible and impactful solutions for Nigeria's immunization program

Study finds feasible and impactful solutions for Nigeria's immunization program

Pfizer’s Prevnar 13 Phase 3 study for pneumococcal disease meets all study endpoints

Pfizer’s Prevnar 13 Phase 3 study for pneumococcal disease meets all study endpoints

Pfizer responds to CDC’S ACIP discussion related to use of Prevnar 13 in adults over 50

Pfizer responds to CDC’S ACIP discussion related to use of Prevnar 13 in adults over 50

Study investigates how bacteria change their disguise to evade vaccines

Study investigates how bacteria change their disguise to evade vaccines

Pfizer’s Prevenar 13 gets US approval for adults

Pfizer’s Prevenar 13 gets US approval for adults

FDA approves Prevnar 13 pneumococcal conjugate vaccine for adults 50 and older

FDA approves Prevnar 13 pneumococcal conjugate vaccine for adults 50 and older

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine as a single dose for adults

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine as a single dose for adults

Pfizer enters Prevenar 13 supply agreement to protect children from pneumococcal disease

Pfizer enters Prevenar 13 supply agreement to protect children from pneumococcal disease

Pneumococcal vaccine Prevnar13 effective in seniors

Pneumococcal vaccine Prevnar13 effective in seniors

Senior UK Parliamentarians visit Bangladesh to see full impact of pneumonia on children

Senior UK Parliamentarians visit Bangladesh to see full impact of pneumonia on children

Private sector companies should contribute to GAVI Matching Fund

Private sector companies should contribute to GAVI Matching Fund

Supplemental dose of pneumonia vaccine recommended for age-eligible patients

Supplemental dose of pneumonia vaccine recommended for age-eligible patients

EC approves Pfizer's pneumococcal conjugate vaccine, Prevenar 13

EC approves Pfizer's pneumococcal conjugate vaccine, Prevenar 13

Pfizer's Prevnar 13: Additional data from adult clinical studies presented at 49th IDSA

Pfizer's Prevnar 13: Additional data from adult clinical studies presented at 49th IDSA

Study highlights importance of prior planning before introduction of new vaccines

Study highlights importance of prior planning before introduction of new vaccines

Researchers discover how a novel type of antibody works against pneumococcal bacteria

Researchers discover how a novel type of antibody works against pneumococcal bacteria

Burundi becomes 10th African country to protect children from pneumonia through immunisation

Burundi becomes 10th African country to protect children from pneumonia through immunisation

Pfizer second-quarter revenues decrease 1% to $17.0 billion

Pfizer second-quarter revenues decrease 1% to $17.0 billion

FDA issues 90-day extension for Pfizer's Prevnar 13 sBLA to treat pneumonia in adults

FDA issues 90-day extension for Pfizer's Prevnar 13 sBLA to treat pneumonia in adults

Developing new antipoverty vaccines may eliminate world's neglected diseases, says Sabin president

Developing new antipoverty vaccines may eliminate world's neglected diseases, says Sabin president